CSL began as a government laboratory making vaccines for Australians. Today it is a global biotech giant built on donated blood plasma. Here’s how it makes its money, and why it has been through a rough patch.
CSL is Australia’s largest biotechnology company and one of the biggest companies on the ASX.
It started in 1916 as the Commonwealth Serum Laboratories, a government body set up to make vaccines and medicines for Australians. It was privatised and listed on the ASX in 1994, and has since grown into a global business that sells its medicines in more than 100 countries.
CSL reports in U.S. dollars, because most of its sales are overseas. Its financial year ends on 30 June.
Plasma, vaccines and iron
The biggest part of the business is CSL Behring, which brought in about US$11.4 billion of revenue in the 2026 financial year.
It collects plasma, the liquid part of blood, from donors at collection centres, mostly in the U.S. The plasma is then separated into proteins and turned into treatments. Its most important products are immunoglobulins, which help people with weakened immune systems fight infection, along with albumin and treatments for bleeding disorders such as haemophilia.
Plasma medicines are expensive and difficult to make, and collecting plasma takes a large network of centres, so there are only a handful of major producers worldwide.
CSL Seqirus is one of the world’s largest makers of flu vaccines. It also makes vaccines in Melbourne for Australia, including for pandemics. CSL had planned to split it off into a separate company, but delayed that plan in October 2025.


CSL Vifor, bought in 2022 for about US$11.7 billion, sells treatments for iron deficiency and kidney disease. Some of its iron products now face cheaper generic competition.
A reset
CSL’s 2026 financial year was a reset. Chief executive Paul McKenzie retired in February 2026, and long-time senior executive Gordon Naylor became interim chief executive. The company wrote down the value of parts of the business, including Vifor, and is cutting costs, closing some underperforming U.S. plasma centres and reducing its workforce.
In October 2026, CSL named Deborah Waterhouse, the head of HIV drug company ViiV Healthcare, as its next chief executive, starting on 1 February 2027.
The risks include the cost of collecting plasma, competition from new drugs that could reduce demand for some plasma treatments, pricing pressure from governments, and changes to health policy in the U.S., its biggest market.
Latest results, as at 9 November 2026
Full year to June 2026, reported 18 August 2026: revenue fell 1 per cent to US$15.8 billion, and underlying profit fell 2 per cent to US$3.1 billion. After US$7.1 billion of write-downs and restructuring costs, CSL posted a statutory loss of US$2.6 billion. It held its dividend steady and announced a $1 billion share buyback.
For the 2027 financial year, CSL expects underlying profit to grow about 5 per cent, with Behring sales growing, while Vifor’s revenue is expected to fall about 25 per cent because of generic competition. Its shares had their best day in more than 20 years after the result.
Next update: CSL reports its half-year results, to December 2026, in February 2027.






















Comments
No comments yet. Start the conversation.